Processa Pharmaceuticals, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
General and administrative personnel costs include employee stock-based compensation expense	$ 629,514	$ 2,371,214
Research and Development Expense [Member]
General and administrative personnel costs include employee stock-based compensation expense	169,414	363,956
General and Administrative Expense [Member]
General and administrative personnel costs include employee stock-based compensation expense	460,100	2,007,258
General and Administrative Expense [Member] \| CorLyst, LLC [Member]
General and administrative personnel costs include employee stock-based compensation expense	$ 186,925	$ 387,854